TPP reduces patent flexibility for generic drugs: AIDS Coalition
The Jakarta Post
Before joining the Trans-Pacific Partnership (TPP) Indonesia might have to assess clauses in the pact that affect the government's capacity to provide affordable vital medicines to the public.
Indonesian AIDS Coalition spokesman Aditya Wardhana said that countries such as India applied beneficial aspects the World Trade Organization (WTO) administered Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, which allows exceptions for some essential drugs.
"Under the TRIPS-Flexibility clause, India has canceled the patents of expensive essential medicines for cancer, AIDS [acquired immunodeficiency syndrome] and hepatitis. India is now the biggest producer of generic medicines in the world," he said on Monday in Jakarta.
The optimism for affordable medicine for the public was sparked when President Joko Widodo announced collaboration with India in developing the Indonesian pharmaceutical industry, allowing the country to learn how to maximize TRIPS flexibility to provide cheap generic medicines for the public.
However, Aditya said that optimism might fade if Indonesia joins the US-led free trade agreement as it had a TRIPS-plus ratification that led to an increase in patent periods and the scope of the powers of patent holders.
"If Indonesia joins the TPP, patent holders will use TRIPS-plus and sue the government for producing generic medicines as a violation of their patent rights," he warned. (ags)
- Papuan rebel leader reiterates call for referendum
- From sex to murder: Dark face of Indonesian cults
- World’s first dengue vaccine now available in Indonesia
- 1, 2, 3: The order is Agus, Ahok, Anies
- Tax reform to follow last ever amnesty
- Hundreds of supporters accompany candidates to pick ballot numbers
- UN wildlife campaign goes live on RI social media
- Jokowi lays wreath for Thailand's King Bhumibol
- Int’l students participate in IPB scientific seminar, symposium
- Better fiscal control saves Indonesia's economy